Long-term Immunogenicity of a Single Dose of Japanese Encephalitis Chimeric Virus Vaccine in Toddlers and Booster Response 5 Years After Primary Immunization
Authors:
- Veerachai WatanaveeradejVWVeerachai Watanaveeradej
- Chitsanu PancharoenCPChitsanu Pancharoen
- Maria Rosario CapedingMCMaria Rosario Capeding
- Emmanuel FeroldiEFEmmanuel Feroldi
- Alain BouckenoogheABAlain Bouckenooghe
- 1 April 2017
- journal article
- research article
- Published by Wolters Kluwer Health in The Pediatric Infectious Disease Journal
- Vol. 36 (4) , e108-e113
Abstract
Japanese encephalitis (JE) is an important mosquito-borne viral disease that is endemic in Asia, Western Pacific countries and Northern Australia. Although there is no antiviral treatment, vaccination is effective in preventing this disease. We followed a cohort of 596 children for 5 years after primary vaccination at 12-18 months of age with JE chimeric virus vaccine (JE-CV; IMOJEV) in a multicenter, phase III trial in Thailand and the Philippines to assess antibody persistence and safety. At the end of the 5 years, a subgroup of 85 participants, at 1 site in Thailand, was followed after administration of a JE-CV booster vaccination. JE antibody titers were measured annually after primary vaccination and 28 days after booster vaccination using a 50% plaque reduction neutralization test. Seroprotection was defined as a JE-CV neutralizing antibody titer ≥10 (1/dil). Kaplan-Meier survival analysis was used to estimate the proportion of participants maintaining protective JE-CV neutralizing antibody titers. At 1, 2, 3, 4 and 5 years after vaccination with JE-CV, 88.5%, 82.9%, 78.2%, 74.0% and 68.6% of the participants followed remained seroprotected. Geometric mean titers in the subgroup assessed after receipt of a booster dose increased from 61.2 (95% confidence interval: 43.8-85.7) pre-booster to 4951 (95% confidence interval: 3928-6241) 28 days post-booster, with all participants seroprotected. There were no safety concerns identified. Protective immune responses persisted for at least 5 years after a JE-CV primary immunization in the majority of participants. JE-CV booster induced a robust immune response even after a 5-year interval.Keywords
This publication has 17 references indexed in Scilit:
- Concomitant administration of live attenuated Japanese encephalitis chimeric virus vaccine (JE-CV) and measles, mumps, rubella (MMR) vaccine: Randomized study in toddlers in TaiwanVaccine, 2014
- Memory immune response and safety of a booster dose of Japanese encephalitis chimeric virus vaccine (JE-CV) in JE-CV-primed childrenHuman Vaccines & Immunotherapeutics, 2013
- Single-dose, live-attenuated Japanese encephalitis vaccine in children aged 12–18 months: Randomized, controlled phase 3 immunogenicity and safety trialHuman Vaccines & Immunotherapeutics, 2012
- Estimated global incidence of Japanese encephalitis:Bulletin of the World Health Organization, 2011
- Safety and Immunogenicity of a Single Administration of Live-attenuated Japanese Encephalitis Vaccine in Previously Primed 2- to 5-year-olds and Naive 12- to 24-month-oldsThe Pediatric Infectious Disease Journal, 2010
- Long term immunity to live attenuated Japanese encephalitis chimeric virus vaccineHuman Vaccines, 2010
- Report on a WHO consultation on immunological endpoints for evaluation of new Japanese encephalitis vaccines, WHO, Geneva, 2–3 September, 2004Vaccine, 2005
- Flavivirus EncephalitisNew England Journal of Medicine, 2004
- Japanese viral encephalitisPostgraduate Medical Journal, 2002
- New initiatives for the control of Japanese encephalitis by vaccination:Vaccine, 2000